US FDA approves Novartis’ $475, zero CAR-T cell cancer therapy

‘A fresh frontier:’ US FDA approves Novartis’ $475,000 CAR-T cell cancer therapy By Dan Stanton+ Dan Stanton 31-Aug-2017 2017-08-31T00:00:00Z Last updated on 31-Aug-2017 at 14:13 GMT 2017-08-31T14:13:51Z Kymriah (tisagenlecleucel), made at the former-Dendreon site in Fresh Jersey, has become the very first gene modified cell therapy to be approved in the US. “We’re injecting a […]